BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN, L2
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Agreement to Acquire
And Reach Global Settlement
Other Events
Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
Shareholder votes
Q3
Q2
Q1
FY 2024
FY 2023 amended
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration of Securities
Effectiveness Notice
Additional Proxy Materials
Additional Proxy Soliciting Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership